WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. - Wikidata - awgldk - TriplyDB

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.

http://www.wikidata.org/entity/Q37731754

about

New Strategies for the Treatment of Solid Tumors with CAR-T Cells New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens Carbon nanotubes as vaccine scaffolds Current issues in malignant pleural mesothelioma evaluation and management Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia Novel immunotherapy clinical trials in malignant pleural mesothelioma.Trial watch: Immunostimulatory cytokines in cancer therapy.A novel minigene scaffold for therapeutic cancer vaccines Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.Novel therapies in phase II and III trials for malignant pleural mesothelioma.Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation.Lung cancer: Biology and treatment options.Fowlpox-based survivin vaccination for malignant mesothelioma therapy Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen Wilms' tumour suppressor gene 1 (WT1) is involved in the carcinogenesis of Lung cancer through interaction with PI3K/Akt pathway.Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.Understanding CD8+ T-cell responses toward the native and alternate HLA-A*02:01-restricted WT1 epitope.Novel targeted therapies and vaccination strategies for mesothelioma.Next-generation peptide vaccines for advanced cancer.Therapies currently in Phase II trials for malignant pleural mesothelioma.Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.Immune therapies for malignant mesothelioma.Searching for targets for the systemic therapy of mesothelioma.Immunotherapy prospects in the treatment of lung cancer and mesothelioma.Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).Immune Therapy.An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules.A catalogue of treatment and technologies for malignant pleural mesothelioma.Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.Immunotherapy for malignant mesothelioma: Reality check.

P2860

Q26748500-A04AAE5B-8EB5-4476-8B34-61FE3A10E037 Q26859274-8A1CB886-4350-4BA9-840D-F2349504F33D Q27026836-7FB90BAF-354D-4407-8800-E50332E28E15 Q28390624-171865AC-AA81-4617-BA08-32594A18EE40 Q28392532-17611E99-19AB-41D2-BDB6-5A826C6909BB Q28393560-F370D88C-FEFF-4310-A08E-4EF6A653C00A Q28395597-67067FAA-F2D9-435F-BE6C-8DBBDC5477A2 Q31155155-0924793C-C2AD-49E8-8E12-EA62EE3A4BA5 Q33849643-1EF33EF5-C25F-4539-9045-647062A535D4 Q33871577-8637A649-EF50-4F4B-A95F-4381506023E3 Q33880165-2032C016-5002-4F8B-A815-813EA62347AE Q34418540-4EF8B7B7-40E9-4492-9E75-75E2C2BB121B Q34613585-7885A7BC-62C2-42BB-B80F-24B6CF51265F Q35000449-F8AC5AFC-964A-4BEE-8267-81DF94821433 Q35042668-BBBCA695-C77A-42C0-9AF8-7151B1E36D7C Q35129535-44607FC7-D0E2-4F5D-A00D-1EF15C290C37 Q35182037-95938E9D-AA2D-479F-9D04-D0F55496D5C1 Q35711576-0F95A483-A196-45C7-9D6E-74AF80000055 Q35889240-DE3060C4-E69A-4CB4-8739-802B2B2C36CA Q36328370-3BC9A24B-7AC4-49FC-BC3E-CFBE035D5A66 Q36874759-9679B559-EDED-4B67-919A-B3DB2376A033 Q37083610-414EE919-67CE-4AA8-9225-B94810FE5084 Q37148167-E9365EE2-39D3-47DD-9B4D-5A22B1E96F5E Q37322906-B3A88D0F-E1F5-418C-AB14-21312C86C090 Q37355213-90C431BF-885B-41FE-8C72-7FCD2DC8C70F Q37659113-C56F5243-4F78-4A46-B18D-73E643ACF09A Q37739362-CBD00B77-526D-47C8-9C73-34860C985303 Q37855667-B7997CB0-14CD-4706-8AAA-D502E24BD027 Q38056246-3BF39193-8E50-4C0B-8068-698F1FF5AC3E Q38118385-0E087260-1F53-435C-8448-646CF3BA9856 Q38180749-427DB728-55EE-491A-A9B4-D09EA663ED5E Q38212149-12585EA5-E624-4782-9921-FC63908AECA6 Q38365768-1C161CE9-EAE9-4EE3-91AB-4FC8AAA3DBC6 Q38390104-65728EBC-0EC8-4E64-A4FB-71D730E27C32 Q38399051-C1D64278-17BA-45A5-BFF2-417FF37633F1 Q38669273-7019B13B-CF2D-483B-89F4-883DA973D2CB Q38739446-9FC09C1D-1B32-4C11-B390-9AE533531320 Q38760623-3E2AA6E1-DF97-469B-91AE-E3C386093D55 Q38890122-8706BA77-344A-4485-B02E-B0415A2690FB Q39351008-0E671339-09A8-4809-BA42-691222CD4892

P2860

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.

http://www.wikidata.org/entity/Q37731754

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 June 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

WT1 peptide vaccinations induc ...... nd non-small cell lung cancer.

@en

WT1 peptide vaccinations induc ...... nd non-small cell lung cancer.

@nl

type

label

WT1 peptide vaccinations induc ...... nd non-small cell lung cancer.

@en

WT1 peptide vaccinations induc ...... nd non-small cell lung cancer.

@nl

prefLabel

WT1 peptide vaccinations induc ...... nd non-small cell lung cancer.

@en

WT1 peptide vaccinations induc ...... nd non-small cell lung cancer.

@nl

P1433

Q37731754-4A519198-7A57-4B2C-A39A-725691C514DD

P1476

Q37731754-B4DD22DC-3BBA-48D4-B0BD-464611C81438

P2093

Q37731754-1A18DCA0-FB7B-42A3-B77F-A4B1847C953D

Q37731754-21380371-FAAC-4FE1-82D1-AE483F320AC6

Q37731754-4D8BE4D2-DE97-4B2B-A905-81A40965D3DB

Q37731754-759D6B1F-5585-4082-B732-8CC637F4949D

Q37731754-9BCAB020-AFE1-4D10-9C1C-DF1089A38460

Q37731754-9F776D0F-786B-4CF0-97E8-C8C0FD8A32EB

Q37731754-A6CE4CC8-4C0F-4D45-B6E6-0FAA16E7151F

Q37731754-A6D7925B-2D88-4A92-A9F9-CAB1F14335BB

Q37731754-B99FCD72-3BD0-4039-B134-797BB479A291

Q37731754-EDBBCA4D-9F15-4B3D-9F6E-97AB5737C140

P2860

Q37731754-07315567-DD67-4790-9CB5-DD3741F594F2

Q37731754-07782899-D6DB-4C16-8390-162F76133765

Q37731754-0D6B5508-CD68-4E39-93C1-08638D90395D

Q37731754-1E4AF795-14C0-4930-94AF-0D46A2066B5F

Q37731754-216DFB28-EE1C-4718-B706-06459913609C

Q37731754-4199BFAC-B02F-45A4-A535-1BA991B49AFD

Q37731754-4C9BA25B-6DEE-47AE-B5C1-D8CA7ED9407F

Q37731754-619919C5-CFBE-48A9-BECC-DB9DFF9ECE53

Q37731754-70193F61-9538-440F-9B51-EB9E21F00DA7

Q37731754-7CD7F6F0-B8C8-472A-B38C-82742B7793FC

P2888

Q37731754-AB0FFFE6-AE6F-47FE-A2E4-A1C50BFF6005

P304

Q37731754-8FC08802-F5E5-447A-B0C1-3D697090171B

P31

Q37731754-9C2EB163-970E-4A9B-A966-84172D81FD15

P356

Q37731754-860BC579-C915-4B7A-B4DB-059F193E800E

P433

Q37731754-DACA6666-52D5-4245-B1F5-04198E9CD855

P478

Q37731754-14669256-1E00-4BAD-8910-CFCB3324D382

P50

Q37731754-D39A2772-D61A-479F-ADD5-FCF3A99952FB

P577

Q37731754-256B2D21-E968-41BC-AA68-305D9D4076BA

P5875

Q37731754-7671BA56-3765-4799-A319-7DC425605028

P698

Q37731754-120BACC4-E556-4CF8-B0B3-1A4B7B8F9A67

P921

Q37731754-96375688-3977-4BE5-AAB0-5275C034D751

P932

Q37731754-9A0E6203-F94B-4132-8C14-00DA6A0421B2

P356

S00262-010-0871-8

P1433

Cancer Immunology, Immunotherapy

P1476

WT1 peptide vaccinations induc ...... and non-small cell lung cancer

@en

P2093

Andrew B Brown

http://www.w3.org/2001/XMLSchema#string

David A Scheinberg

http://www.w3.org/2001/XMLSchema#string

Hao Li

http://www.w3.org/2001/XMLSchema#string

Jedd Wolchok

http://www.w3.org/2001/XMLSchema#string

Jianda Yuan

http://www.w3.org/2001/XMLSchema#string

Lee M Krug

http://www.w3.org/2001/XMLSchema#string

Leslie Tyson

http://www.w3.org/2001/XMLSchema#string

Sara Bekele

http://www.w3.org/2001/XMLSchema#string

Tao Dao

http://www.w3.org/2001/XMLSchema#string

Tatyana Korontsvit

http://www.w3.org/2001/XMLSchema#string

P2860

T-cell quality in memory and protection: implications for vaccine design

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

A clinical development paradigm for cancer vaccines and related biologics.

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.

The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.

Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

P2888

s00262-010-0871-8

P304

1467-1479

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-010-0871-8

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44658170

http://www.w3.org/2001/XMLSchema#string

P698

20532500

http://www.w3.org/2001/XMLSchema#string

P921

P932

4004362

http://www.w3.org/2001/XMLSchema#string